Eupraxia's EP-104IAR secures US FDA Fast Track status
Eupraxia has received Fast Track designation from the US FDA for EP-104IAR to treat osteoarthritis of the knee in adult patients.
Page 2 - James Helliwell News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from James Helliwell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In James Helliwell Today - Breaking & Trending Today
Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results
/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug...
Source: newswire.ca
ESG: Is there too much focus on the E?
The environmental aspect of the ESG strategies has overtaken the discussion in the sector, to the detriment of the social factor.
Source: offshore-energy.biz
C2I Wildcard Winner: Floating on Air
Retrofitting Shell’s Patricia Camila LNG tanker with air lubricationled to significant fuel and emissions savings for the giant vessel. Andrew Wade reports.
Source: theengineer.co.uk